ウロピリジンUropyridin(エーザイ)の使用経験

Abstract

Clinical evaluation of Uropyridin (the Eisai Ph a rmaceutical Co., phenylazo-diaminopyridine HC1) as an allopathic agent for the irritable bladder syndrome have been undertaken. It is found that Uropyridin is effective in quick relief of the irritable bladder syndrome and when the syndrome is persistent and it is not relieved by the other, drugs or allopathic treatment. Uropyridin in combination with chemotherapy or antibiotic therapy is capable of improving symptoms caused by bacterial cystitis. Therapy with Uropyridin will be recommended on a dosa g e schedule of 150-200 mgm. three times daily. According to our clinical trials with Uropyridine, its indications are as follows 1. Cystitis, urethritis, prostatitis and the irritable bladder syndrome in female whose objective findings is minimum while significant subjective complaints are present. 2 Irritable bladder syndrome associated with hypertrophy of the prostate. 3. Irritable bladder syndrome due to the ureteral stone or indwelling catheter. 4. Analgesia for operative wound and the mucous membrane of the urinary tract after urological operation and diagnostic procedure. Side effect encountered in our 22 cases was nausea which occurred in only one case with the irritable bladder. Since patient's urine on this therapy is orange colored, it is advised to inform them that the coloring is due to Uropyridin administration. In the United States, 1% solution o f Uropyridin is widely utilyzed for the purpose of surface anesthesia for urological instrumentation in children. Authors suggest that it is also worth to put on trial.